Cancer Biology & Medicine

Papers
(The H4-Index of Cancer Biology & Medicine is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Eliminating cervical cancer: a global health imperative for women225
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy129
The Warburg effect drives dedifferentiation through epigenetic reprogramming69
A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer57
Artificial intelligence in breast cancer: applications and advancements56
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity53
Early-onset gastric cancer global burden profile, trends, and contributors52
Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma47
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance46
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer45
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up42
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer37
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives37
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies36
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer33
<italic>Bifidobacterium animalis</italic> suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8<sup>&#x002B;</sup> T cells33
Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications33
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente31
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis30
Lung cancer mortality trends in China from 2013 to 2021 and projections to 203029
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment28
Immune checkpoint inhibitors: breakthroughs in cancer treatment28
Cancer stem cells: a target for overcoming therapeutic resistance and relapse27
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC27
Biological mechanism and immune response of MHC-II expression in tumor cells27
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis25
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer25
Chinese expert consensus on additional surgery following endoscopic resection for early colorectal cancer (2025 edition)25
0.169105052948